Subclinical atherosclerosis: What it is, what it means and what we can do about it

International Journal of Clinical Practice

Volumn 62, Issue 8, 2008, Pages 1246-1254

  Toth, P P ^a,b  

^a Sterling Rock Falls Clinic ^*  (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ANGIOCARDIOGRAPHY; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; B SCAN; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DISEASE COURSE; DISEASE SEVERITY; DRUG MEGADOSE; ELECTRON BEAM TOMOGRAPHY; GENETIC SUSCEPTIBILITY; HUMAN; HYPERTENSION; IMMOBILIZATION; INFLAMMATION; INTRAVASCULAR ULTRASOUND; INVASIVE PROCEDURE; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MONOTHERAPY; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PREVENTION AND CONTROL; PRIORITY JOURNAL; RADIODIAGNOSIS; REVIEW; RISK FACTOR; SCREENING TEST; SITTING; VASCULAR ENDOTHELIUM;

ADULT; AGED; ATHEROSCLEROSIS; CAROTID ARTERY DISEASES; CORONARY DISEASE; DISEASE PROGRESSION; EARLY DIAGNOSIS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIFE STYLE; MALE; MASS SCREENING; MIDDLE AGED; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 47349085329     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01804.x     Document Type: Review

References (68)

1. American Heart Association. Heart Disease and Stroke Statistics: 2007 Update. Dallas, TX : American Heart Association, 2007.
2. CHD Statistics Fact Sheet 2008: United Kingdom. http://www.ws3. heartstats.web.baigent.net/datapage.asp?id=6799 (Accessed May 2008).
3. McNamara JJ, Molot MA, Stremple JF et al. Coronary artery disease in combat casualties in Vietnam. JAMA 1971 216 : 1185 7.
4. Newman WP III, Freedman DS, Voors AW et al. Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis: the Bogalusa Heart Study. N Engl J Med 1986 314 : 138 44.
5. PDAY Research Group. Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking: a preliminary report from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. JAMA 1990 264 : 3018 24.
6. Newman AB, Arnold AM, Naydeck BL et al. 'Successful aging': effect of subclinical cardiovascular disease. Arch Intern Med 2003 163 : 2315 22.
7. Fuster V. Mechanism leading to myocardial infarction: insights from studies of vascular biology. Circulation 1994 90 : 2126 46.
8. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999 340 : 115 26.
9. Zaman AG, Helft G, Worthley SG et al. The role of plaque rupture and thrombosis in coronary artery disease. Atherosclerosis 2000 149 : 251 66.
10. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005 352 : 1685 95.
11. Rao RM, Yang L, Garcia-Cardena G et al. Endothelial-dependent mechanisms of leukocyte recruitment to the vascular wall. Circ Res 2007 101 : 234 47.
12. Virmani R, Kolodgie FD, Burke AP et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis is a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol 2005 25 : 2054 61.
13. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation 2005 111 : 3481 8.
14. Davies JR, Rudd JH, Weissberg PL. Molecular and metabolic imaging of atherosclerosis. J Nucl Med 2004 45 : 1898 907.
15. Burke AP, Kolodgie FD, Farb A et al. Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation 2001 103 : 934 40.
16. Grundy SM. Coronary plaque as a replacement for age as a risk factor in global risk assessment. Am J Cardiol 2001 88 (Suppl. 2A 8E 11E.
17. Devaraj S, Rogers J, Jialal I. Statins and biomarkers of inflammation. Curr Atheroscler Rep 2007 9 : 33 41.
18. Tuzcu EM, Nicholls SJ. Statins: targeting inflammation by lowering low-density lipoprotein? J Am Coll Cardiol 2007 49 : 2010 2.
19. Khera A, de Lemos JA, Peshock RM et al. Relationship between C-reactive protein and subclinical atherosclerosis: the Dallas Heart Study. Circulation 2006 113 : 38 43.
20. Schillinger M, Exner M, Mlekusch W et al. Inflammation and Carotid Artery - Risk for Atherosclerosis Study (ICARAS). Circulation 2005 111 : 2203 9.
21. Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward a consensus. J Am Coll Cardiol 2007 49 : 2129 38.
22. Ridker PM, on behalf of the JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Circulation 2003 108 : 2292 7.
23. Kuller L, Borhani N, Furberg C et al. Prevalence of subclinical atherosclerosis and cardiovascular disease and association with risk factors in the Cardiovascular Health Study. Am J Epidemiol 1994 139 : 1164 79.
24. Jaffer FA, O'Donnell CJ, Larson MG et al. Age and sex distribution of subclinical aortic atherosclerosis: a magnetic resonance imaging examination of the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2002 22 : 849 54.
25. Sutton-Tyrell K, Kuller LH, Matthews KA et al. Subclinical atherosclerosis in multiple vascular beds: an index of atherosclerotic burden evaluated in postmenopausal women. Atherosclerosis 2002 160 : 407 16.
26. Michos ED, Vasamreddy CR, Becker DM et al. Women with a low Framingham risk score and a family history of premature coronary heart disease have a high prevalence of subclinical coronary atherosclerosis. Am Heart J 2005 150 : 1276 81.
27. Lee TC, O'Malley PG, Feuerstein I et al. The prevalence and severity of coronary artery calcification on coronary artery computed tomography in black and white subjects. J Am Coll Cardiol 2003 41 : 39 44.
28. Nasir K, Santos RD, Tufail K et al. High-normal fasting glucose in non-diabetic range is associated with increased coronary artery calcium burden in asymptomatic men. Atherosclerosis 2007 195 : e155 60 Epub 2 July 2007.
29. Tzou WS, Douglas PS, Srinivasan SR et al. Increased subclinical atherosclerosis in young adults with metabolic syndrome: the Bogalusa Heart Study. J Am Coll Cardiol 2005 46 : 457 63.
30. McNeill AM, Rosamond WD, Girman CJ et al. Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (the ARIC Study). Am J Cardiol 2004 94 : 1249 54.
31. Ingelsson E, Sullivan LM, Murabito JM et al. Prevalance and prognostic impact of subclinical cardiovascular disease in individuals with the metabolic syndrome and diabetes. Diabetes 2007 56 : 1718 26.
32. Schurgin S, Rich S, Mazzone T. Increased prevalence of significant coronary artery calcification in patients with diabetes. Diabetes Care 2001 24 : 335.
33. Zeina AR, Odeh M, Rosenschein U et al. Coronary artery disease among asymptomatic diabetic and nondiabetic patients undergoing coronary computed tomography angiography. Coron Artery Dis 2008 19 : 37 41.
34. Heiss G, Sharett AR, Barnes R et al. Carotid atherosclerosis measured by B-mode ultrasound in populations: associations with cardiovascular risk factors in the ARIC study. Am J Epidemiol 1991 134 : 250 6.
35. Lorenz MW, Markus HS, Bots ML et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007 115 : 459 67.
36. Taylor AJ, Kent SM, Flaherty PJ et al. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intimal medial thickness. Circulation 2002 106 : 2055 60.
37. Fayad ZA, Fuster V. The human high-risk plaque and its detection by magnetic resonance imaging. Am J Cardiol 2001 88 (Suppl. 42E 5E.
38. Chu B, Hatsukami TS, Polissar NL et al. Determination of carotid artery atherosclerotic lesion type and distribution in hypercholesterolemic patients with moderate carotid stenosis using noninvasive magnetic resonance imaging. Stroke 2004 35 : 2444 8.
39. Schmermund A, Mohlenkamp S, Erbel R. Coronary artery calcium and its relationship to coronary artery disease. Cardiol Clin 2003 21 : 521 34.
40. Shaw LJ, Raggi P, Schisterman E et al. Prognostic value of cardiac risk factors and coronary artery screening for all-cause mortality. Radiology 2003 223 : 826 33.
41. Kondos GT, Hoff JA, Sevrukov A et al. Electron-beam tomography coronary artery calcium and cardiac events: a 37-month follow-up of 5635 initially asymptomatic low- to intermediate-risk adults. Circulation 2003 107 : 2571 6.
42. Greenland P, LaBree L, Azen SP et al. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA 2004 291 : 210 5.
43. Detrano RC, Anderson M, Nelson J et al. Coronary calcium measurements: effect of CT scanner type and calcium measure on rescan reproducibility: MESA study. Radiology 2005 236 : 477 84.
44. Achenbach S. Current and future status on cardiac computed tomography imaging for diagnosis and risk stratification. J Nucl Cardiol 2005 12 : 703 13.
45. Little WC, Constantinescu M, Applegate RJ et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation 1988 78 : 1157 66.
46. DeMaria AN, Narula J, Mahmud E et al. Imaging vulnerable plaque by ultrasound. J Am Coll Cardiol 2006 47 : C32 9.
47. Baldassarre D, Amato M, Pustina L et al. Measurement of carotid intima-media thickness in dyslipidemic patients increases the power of traditional risk factors to predict cardiovascular events. Atherosclerosis 2007 191 : 403 8.
48. Simon A, Chironi G, Levenson J. Performance of subclinical arterial disease detection as a screening test for coronary heart disease. Hypertension 2006 48 : 392 6.
49. Crouse JR III, Byington RP, Bond MG et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol 1995 75 : 455 9.
50. Nissen SE, Tuzcu EM, Schoenhagen P et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004 291 : 1071 80.
51. Nissen SE, Nicholls SJ, Sipahi I et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006 295 : 1556 65.
52. Smilde TJ, van Wissen S, Wollersheim H et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomized, double-blind trial. Lancet 2001 357 : 577 81.
53. Crouse JR III, Raichlen JS, Riley WA et al., for the METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trial. JAMA 2007 297 : 1344 53.
54. Kastelein JJP, Sager PT, de Groot E et al. Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia: design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. Am Heart J 2005 149 : 234 9.
55. Schering-Plough Web Site. Merck/Schering-Plough Pharmaceuticals Provides Results of the ENHANCE Trial (14 January 2008, News Release). http://www.schering-plough.com/schering_plough/news/release.jsp? releaseID1095943 (accessed March 2008).
56. Crestor (Rosuvastatin Calcium) Prescribing Information. Wilmington, DE : AstraZeneca Pharmaceuticals LP, 2007.
57. Hatsukami TS, Zhao X-Q, Kraiss LW et al. Assessment of rosuvastatin treatment on carotid atherosclerosis in moderately hypercholesterolemic subjects using high-resolution magnetic resonance imaging. Eur Heart J 2005 26 : 626 7 Abstract 3700.
58. Raggi P, Davidson M, Callister TQ et al. Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women: beyond endorsed lipid lowering with EBT scanning (BELLES). Circulation 2005 112 : 563 71.
59. Schmermund A, Achenbach S, Budde T et al. Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial. Circulation 2006 113 : 427 37.
60. Budoff MJ, Achenbach S, Blumenthal RS et al. Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology. Circulation 2006 114 : 1761 91.
61. Greenland P, Bonow RO, Brundage BH et al. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force developed in collaboration with the Society of Atherosclerosis Imaging and Prevention and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol 2007 49 : 378 402.
62. Furberg CD, Adams HP Jr, Applegate WB et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1994 90 : 1679 87.
63. Salonen R, Nyyssönen K, Porkkala E et al. Kuopio Atherosclerosis Prevention Study (KAPS): a population-based primary preventive trial of the effects of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995 92 : 1758 64.
64. Taylor AJ, Sullenberger LE, Lee HJ et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004 110 : 3512 7.
65. Boden WE, O'Rourke RA, Teo KK et al., for the COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007 356 : 1503 16.
66. Cannon CP, Braunwald E, McCabe CH et al., for the Pravastatin or Atorvastatin Evaluation and Infection Therapy - Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004 350 : 1495 504.
67. LaRosa JC, Grundy SM, Waters DD et al., for the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005 352 : 1425 35.
68. Pedersen TR, Faergeman O, Kastelein JJ et al., for the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005 294 : 2437 45.